

UNITED STA. J DEPARTMENT OF COMMERCE Patent and Trademark Office

Address:

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		•			М
APPLICATION NO.	FILING DATE	FIRST NAMED INVE	NTOR		ATTORNEY DOCKET NO.
09/478,621	01/05/0	0 EPSTEIN		s	674522-2001
•		HM12/0227	コ		EXAMINER
Thomas J Kowalski Esq Frommer Lawrence & Haug LLP				JIANG, D	
745 Fifth	wrence & H Avenue	aug LLP		ART UNIT	PAPER NUMBER
New York N				1646	6
	•		٠	DATE MAILED:	02/27/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant/s)					
Office Action Summary			Applicant(s)					
		09/478,621	EPSTEIN ET AL.					
	omee Action Summary	Examiner	Art Unit					
		Dong Jiang	1646					
Period fo	The MAILING DATE of this communication appears Reply	ears on the cover sheet with the co	prrespondence address					
THE - Exte after - If the - If NC - Failu - Any I	ORTENED STATUTORY PERIOD FOR REPL' MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period or re to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36 (a). In no event, however, may a reply be till y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	mely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
1)	Responsive to communication(s) filed on	·						
2a)□	•	nis action is non-final.						
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
4)⊠	4)⊠ Claim(s) <u>1-11</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)⊠	Claims <u>1-11</u> are subject to restriction and/or	election requirement.						
Applicat	ion Papers							
9) The specification is objected to by the Examiner.								
10)	0)☐ The drawing(s) filed on is/are objected to by the Examiner.							
11)	11) The proposed drawing correction filed on is: a) approved b) disapproved.							
12) The oath or declaration is objected to by the Examiner.								
Priority	under 35 U.S.C. § 119							
_	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
	☐ All b)☐ Some * c)☐ None of:							
·	1. Certified copies of the priority documents have been received.							
	Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
*	application from the International Bu See the attached detailed Office action for a list		ed.					
	Acknowledgement is made of a claim for dom	•						
Attachmei	nt(s)							
16) 🔲 No	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s)	19) 🔲 Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)					

Application/Control Number: 09/478,621

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 3-5 and 8-11, drawn to a composition comprising specific protein agents, a kit thereof and a method of preventing or treating specific conditions using said composition, classified in class 514, subclass 2.
- II. Claims 1-2 and 6-11, drawn to a composition comprising specific nucleic acid agents, a kit thereof and a method of preventing or treating specific conditions using said composition, classified in class 514, subclass 44.

The inventions are distinct, each from the other because:

The proteins of Invention I are related to the nucleic acids of Invention II by virtue of encoding same. The DNA molecule has utility for the recombinant production of the protein in a host cell. Although the DNA molecules and proteins are related since the DNA encodes the specifically claimed protein, they are distinct compositions because they are physically and functionally different, and have different properties and uses. The methods of the inventions are different because they utilize patentably distinct active agents, and because the search for gene therapy is not overlapping with the search for administration of proteins.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 09/478,621

Art Unit: 1646

remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Advisory Information

Any inquiry concerning this communication should be directed to Dong Jiang whose telephone number is 703-305-1345. The examiner can normally be reached on Monday - Friday from 9:00 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564. The fax phone number for the organization where this application or proceeding is assigned is 703-308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

LORRAINE SPECTOR PRIMARY EXAMINER

DJ 478621 2/22/01